Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
NCT02767921 · University of Southern California · PHASE1 · terminated · last registry update 2021-11-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient accrual” | – | Registry record, University of Southern California |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EFNB2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-08-24Also stopped (terminated): University of Southern California, recombinant albumin fusion protein sEphB4-HSA (NCT01642342)
- 2022-04-27Results posted on the registry: Northwestern University, Recombinant EphB4-HSA Fusion Protein (NCT04033432)
- 2021-11-30Also stopped (terminated): University of Southern California, Cytarabine + Recombinant EphB4-HSA Fusion Protein (NCT03519984)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision